A total of 265 patients have been admitted to the trial. Completion of the trial data analysis is expected in the last quarter of 2007. The effect of nemonoxacin in comparison with levofloxacin, the leading quinolone on the market, will be evaluated with both clinical and bacteriological success rates in treating adult patients with community-acquired pneumonia (CAP).
“We are pleased with the efficient manner in which the 18 clinical centers have enrolled patients in the Phase II study,” said Dr Ming Chu Hsu, chairman and CEO of TaiGen. “Completing enrollment in this study shall keep us on track of our projected development timeline for this highly promising antibacterial for the treatments of resistant infection.”